[Multidrug-resistant tuberculosis: A management problem that weighs heavily on the University Hospitals of Strasbourg].

Tuberculose multirésistante : une prise en charge qui pèse lourd aux hôpitaux universitaires de Strasbourg.
Antituberculeux Antituberculous Epidemiology Extensive drug-resistance Multidrug-resistance Multirésistance Tuberculose Tuberculosis Ultra-résistance Épidémiologie

Journal

Revue des maladies respiratoires
ISSN: 1776-2588
Titre abrégé: Rev Mal Respir
Pays: France
ID NLM: 8408032

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 26 06 2018
accepted: 15 07 2019
pubmed: 25 8 2019
medline: 15 5 2020
entrez: 25 8 2019
Statut: ppublish

Résumé

Multidrug-resistant tuberculosis (MDR-TB) is a major public health problem with great regional disparities. The aim of this study was to describe the epidemiological, clinical, and therapeutics aspects of MDR-TB in Alsace, France. A 10 years retrospective study, conducted for the years 2006 to 2016, of all MDR-TB cases diagnosed in Alsace and particularly in Strasbourg University Hospitals. We included 22 patients with MDR-TB of whom 90% originated from Eastern Europe, 13.6% had extensively-resistant strains, and 41% reported previously treated tuberculosis. Clinically, 86,4% had a pulmonary form of tuberculosis. The mean length of antibiotic treatment was 21 months with several changes of drugs because of severe side effects. The mean follow-up was 48 months, during which time 2 patients were lost from contact and the 20 remaining patients were cured. Management of MDR-TB is a real social and medical challenge. Our study shows that the therapeutic protocols used in the management of these patients lead to an unusually high rate of success despite the occurrence of several, sometimes severe, side effects.

Identifiants

pubmed: 31444025
pii: S0761-8425(19)30282-7
doi: 10.1016/j.rmr.2019.07.006
pii:
doi:

Types de publication

Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

1011-1018

Informations de copyright

Copyright © 2019 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

M Paz (M)

Laboratoire de microbiologie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France.

X Argemi (X)

Service des maladies infectieuses et tropicales, nouvel hôpital Civil, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France. Electronic address: xavier_argemi@hotmail.com.

F Schramm (F)

Laboratoire de microbiologie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France.

M Mielcarek (M)

Laboratoire de santé publique, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France.

L Kassegne (L)

Service de pneumologie, nouvel hôpital civil, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France.

Y Hansmann (Y)

Service des maladies infectieuses et tropicales, nouvel hôpital Civil, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France.

P Fraisse (P)

Service de pneumologie, nouvel hôpital civil, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH